p53 peptide vaccine
Biologicalexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 26, 1999 (NCT00001827)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53Immunity, active
TP53 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- p53: 264-272 peptide
- p53 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03406715 | Phase 2 | Mar 29, 2018 | Bristol-Myers Squibb, MultiVir, Inc., University of South Florida |
| NCT01386502 | Phase 1 | Jun 15, 2011 | National Cancer Institute (NCI) |
| NCT00019916 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2000 | National Cancer Institute (NCI) |
| NCT00001827 | Phase 2 | Jul 26, 1999 | National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 3 | 2 | 1999 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| MultiVir, Inc. | For profit | 1 | 0 | 1 | 2018 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1